Justyna Kelly

Director de Operaciones en POINT Biopharma, Inc. (United States) .

39 años

Commercial Services

Health Technology

Consumer Services

Perfil

Justyna Kelly is currently the VP-Medical Isotope Development & Operations at POINT Biopharma, Inc. She was previously the Chief Operating Officer at POINT Biopharma Global, Inc. from 2021 to 2023.
Ms. Kelly received her undergraduate and graduate degrees from McMaster University.

Cargos activos de Justyna Kelly

Empresas	Cargo	Inicio
POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	Director de Operaciones	-

Todos los cargos activos de Justyna Kelly

Antiguos cargos conocidos de Justyna Kelly.

Empresas	Cargo	Fin
POIT BIOP	Director de Operaciones	27/12/2023

Ver el detalle de la experiencia de Justyna Kelly.

Formación de Justyna Kelly.

McMaster University

Graduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Justyna Kelly.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
POIT BIOP	Health Technology

Empresas privadas	1
POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	Commercial Services